Catalent (NYSE: CTLT) and Histogenics (NASDAQ:HSGX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Volatility and Risk
Catalent has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Histogenics has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Catalent and Histogenics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalent presently has a consensus price target of $45.33, indicating a potential upside of 7.02%. Histogenics has a consensus price target of $4.00, indicating a potential upside of 37.46%. Given Histogenics’ stronger consensus rating and higher probable upside, analysts clearly believe Histogenics is more favorable than Catalent.
Institutional & Insider Ownership
99.9% of Catalent shares are owned by institutional investors. Comparatively, 50.5% of Histogenics shares are owned by institutional investors. 1.7% of Catalent shares are owned by insiders. Comparatively, 23.8% of Histogenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Catalent and Histogenics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catalent||$2.08 billion||2.72||$109.80 million||$0.57||74.32|
Catalent has higher revenue and earnings than Histogenics. Histogenics is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
This table compares Catalent and Histogenics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Catalent beats Histogenics on 9 of the 13 factors compared between the two stocks.
Catalent Company Profile
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Histogenics Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.